BLCMライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (5 3月 2024 @ 04:59):

Stats
本日の出来高	6 059.00
平均出来高	28 581.00
時価総額	778 326
EPS	$0 ( 2024-03-29 )
次の収益日	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.112
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-22	Baker Bros. Advisors Lp	Sell	1 941 607	Warrants (right to buy)
2023-11-22	Baker Bros. Advisors Lp	Buy	1 941 607	Common Stock
2023-11-22	Baker Bros. Advisors Lp	Sell	174 742	Warrants (right to buy)
2023-11-22	Baker Bros. Advisors Lp	Buy	174 742	Common Stock
2023-05-05	Baker Bros. Advisors Lp	Buy	0	Common Stock

INSIDER POWER
9.48
Last 91 transactions
Buy: 8 287 527 \| Sell: 2 332 728

Bellicum Pharmaceuticals 相関

10 最も正の相関
CNDT	0.957
FOSL	0.943
VTRS	0.932
TBNK	0.928
SRTS	0.927
RPAY	0.925
FNWB	0.923
GTEC	0.922
LPCN	0.919
GRPN	0.918

10 最も負の相関
TYHT	-0.933
NRDS	-0.905
BLCT	-0.897
CNST	-0.889
EPZM	-0.888
CNCE	-0.878
FLXN	-0.874
XOG	-0.872
AMRB	-0.869
HUGE	-0.86

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Bellicum Pharmaceuticals 財務諸表

Annual	2022
収益:	$1.50M
総利益:	$1.50M (100.00 %)
EPS:	$-0.810

FY	2022
収益:	$1.50M
総利益:	$1.50M (100.00 %)
EPS:	$-0.810

FY	2021
収益:	$6 200.00
総利益:	$6 200.00 (100.00 %)
EPS:	$-0.000844

FY	2020
収益:	$500.00
総利益:	$500.00 (100.00 %)
EPS:	$-0.00134

Financial Reports:

No articles found.

Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.